Disease-specific, or all-cause mortality as an endpoint?

How valid is the use of all-cause mortality in randomized screening trials?

In the light of overdiagnosis, overtreatment and resultant deaths, should all-cause mortality be the end point in randomized screening trials?

This paper examines the validity of disease-specific deaths as an endpoint in randomized cancer screening trials.

‘Because all-cause mortality is not affected by bias in classifying the cause of death, it should be examined when interpreting the results of randomized cancer-screening trials.’
All-Cause Mortality in Randomized Trials of Cancer Screening. William C Black, David A Haggstrom and H Gilbert Welch. Journal of the National Cancer Institute Vol 94, issue 3. Pp 167-173.

About bmitzi

Medical writer, author, artist. Cancer campaigner. Aiming always to improve health services and bring compassion into health care.
This entry was posted in breast screening, Campaigns, cancer, clinical trials, Compassion in healthcare, death, guidelines, healthcare modernisation, information, Screening Mammography, speaking out, Uncategorized and tagged , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s